Odyssey Therapeutics, Inc., a Delaware biotechnology company, is registering an additional 2,599,000 shares of common stock via Rule 462(b) to increase its IPO offering following the effectiveness of prior S-1 (No. 333-295141) on May 7, 2026.
Key takeaways
Filing S-1MEF under Rule 462(b) adds 2,599,000 common shares to prior S-1 registration.
Additional shares valued at $46,782,000 based on $18.00 per share proposed price.
Includes 339,000 shares for underwriters' overallotment option.
Biotech firm in SIC 2836 (pharmaceutical preparations), headquartered in Boston, MA.
Non-accelerated filer, smaller reporting company, and emerging growth company status.
Audited by Deloitte & Touche LLP with report dated March 16, 2026 (updated May 4, 2026).